Condition
Advanced Prostate Adenocarcinoma
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
4Total
P 1 (2)
P 2 (1)
P 3 (1)
Trial Status
Completed2
Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT06173362Phase 2RecruitingPrimary
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
NCT04914195Phase 3CompletedPrimary
Leuprolide Acetate 3.75 mg Depot Injection for Patients With Advanced Prostate Cancer
NCT04843319Phase 1TerminatedPrimary
To Determine an Effective Dose of VERU-100 for the Treatment of Advanced Prostate Cancer
NCT00502164Phase 1CompletedPrimary
Study to Assess Safety and Tolerability of AZD2171 After Multiple Doses in Patients With Advanced Prostate Cancer
Showing all 4 trials